| CMTM6 mediates the Warburg effect and promotes the liver metastasis of colorectal cancer. | CMTM6 mediates the Warburg effect and promotes the liver metastasis of colorectal cancer.
Shaha A, Wang Y, Wang X, Wang D, Guinovart D, Liu B, Kang N., Free PMC Article | 10/9/2024 |
| Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/beta-catenin pathway and acts as an onco-immunological biomarker. | Autophagy-related CMTM6 promotes glioblastoma progression by activating Wnt/β-catenin pathway and acts as an onco-immunological biomarker.
Dai L, Xiao J, Li X, Tao Y, Zhou P, Lyu L, Shi Z, Liang X, Jia Z, Jiang S. | 05/8/2024 |
| From patient tissue correlates to molecular mechanisms of cancer immune evasion: the emerging role of CD58 and PD-L1 co-regulation via CMTM6. | From patient tissue correlates to molecular mechanisms of cancer immune evasion: the emerging role of CD58 and PD-L1 co-regulation via CMTM6.
Melms JC, Ho P, Rogava M, Izar B. | 02/20/2024 |
| CMTM 6 promotes the development of thyroid cancer by inhibiting NIS activity through activating the MAPK signaling pathway. | CMTM 6 promotes the development of thyroid cancer by inhibiting NIS activity through activating the MAPK signaling pathway.
Chen X, Shen H, Liu H, Tan L, Zhang N. | 02/15/2024 |
| Bioinformatics analysis of CMTM family in pan-cancer and preliminary exploration of CMTM6 in bladder cancer. | Bioinformatics analysis of CMTM family in pan-cancer and preliminary exploration of CMTM6 in bladder cancer.
Xu Y, Li Q, Lin H. | 02/2/2024 |
| Transmembrane Protein CMTM6 Alleviates Ocular Inflammatory Response and Improves Corneal Epithelial Barrier Function in Experimental Dry Eye. | Transmembrane Protein CMTM6 Alleviates Ocular Inflammatory Response and Improves Corneal Epithelial Barrier Function in Experimental Dry Eye.
Zhou Y, Ma B, Liu Q, Duan H, Huo Y, Zhao L, Chen J, Han W, Qi H., Free PMC Article | 01/4/2024 |
| CMTM6 recruits T cells within the endocervical adenocarcinoma microenvironment and suppresses cell proliferation via the p53 pathway. | CMTM6 recruits T cells within the endocervical adenocarcinoma microenvironment and suppresses cell proliferation via the p53 pathway.
Liang HY, Chen SL, Cai SH, Zhang SW, Yang X, Wei LJ, Luo RZ, Liu LL. | 03/30/2023 |
| CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis. | CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis.
Jia D, Xiong L, Xue H, Li J., Free PMC Article | 01/21/2023 |
| CMTM6 attenuates cisplatin-induced cell death in OSCC by regulating AKT/c-Myc-driven ribosome biogenesis. | CMTM6 attenuates cisplatin-induced cell death in OSCC by regulating AKT/c-Myc-driven ribosome biogenesis.
Mohapatra P, Mohanty S, Ansari SA, Shriwas O, Ghosh A, Rath R, Majumdar SKD, Swain RK, Raghav SK, Dash R. | 01/14/2023 |
| CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer. | CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer.
Xing F, Gao H, Chen G, Sun L, Sun J, Qiao X, Xue J, Liu C., Free PMC Article | 01/14/2023 |
| Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer. | Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer.
Xue H, Qiu B, Wang H, Jiang P, Zhang W, Xue L, Wang J., Free PMC Article | 10/29/2022 |
| CMTM6 as a master regulator of PD-L1. | CMTM6 as a master regulator of PD-L1.
Yaseen MM, Abuharfeil NM, Darmani H., Free PMC Article | 09/24/2022 |
| CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment. | CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment.
Zhang T, Yu H, Dai X, Zhang X., Free PMC Article | 08/27/2022 |
| The clinical and prognostic significance of CMTM6/PD-L1 in oncology. | The clinical and prognostic significance of CMTM6/PD-L1 in oncology.
Yaseen MM, Abuharfeil NM, Darmani H. | 07/23/2022 |
| The predictive value and correlation of beta-catenin, CMTM6, and PD-L1 expression in colorectal cancer. | The predictive value and correlation of β-catenin, CMTM6, and PD-L1 expression in colorectal cancer.
Li B, Wu S, Qiu Z, Zhong X, Chen Z, Luo F, Li J, Liu K. | 06/18/2022 |
| CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3beta axis. | CMTM6 drives cisplatin resistance by regulating Wnt signaling through the ENO-1/AKT/GSK3β axis.
Mohapatra P, Shriwas O, Mohanty S, Ghosh A, Smita S, Kaushik SR, Arya R, Rath R, Das Majumdar SK, Muduly DK, Raghav SK, Nanda RK, Dash R., Free PMC Article | 01/15/2022 |
| CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma. | CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
Yugawa K, Itoh S, Yoshizumi T, Iseda N, Tomiyama T, Morinaga A, Toshima T, Harada N, Kohashi K, Oda Y, Mori M., Free PMC Article | 12/25/2021 |
| CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer. | CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer.
Peng QH, Wang CH, Chen HM, Zhang RX, Pan ZZ, Lu ZH, Wang GY, Yue X, Huang W, Liu RY., Free PMC Article | 12/18/2021 |
| CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer. | CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer.
Wu X, Lan X, Hu W, Zhang W, Lai X, Xu S, Li J, Qiu W, Wang W, Xiao J, Wang F, Ding Y, Liang L., Free PMC Article | 10/16/2021 |
| HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer. | HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer.
Liu Y, Li X, Zhang H, Zhang M, Wei Y., Free PMC Article | 10/16/2021 |
| CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma. | CMTM6 and PD-1/PD-L1 overexpression is associated with the clinical characteristics of malignancy in oral squamous cell carcinoma.
Zhang S, Yan Q, Wei S, Feng X, Xue M, Liu L, Cui J, Zhang Y. | 10/9/2021 |
| High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence. | High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence.
Muranushi R, Araki K, Yokobori T, Chingunjav B, Hoshino K, Dolgormaa G, Hagiwara K, Yamanaka T, Ishii N, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, Harimoto N, Shimoda Y, Sano R, Oyama T, Saeki H, Shirabe K., Free PMC Article | 08/21/2021 |
| CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma. | CMTM6 is positively correlated with PD-L1 expression and immune cells infiltration in lung squamous carcinoma.
Shang X, Li J, Wang H, Li Z, Lin J, Chen D, Wang H. | 06/12/2021 |
| CMTM5/7 are biomarkers and prognostic factors in human breast carcinoma. | CMTM5/7 are biomarkers and prognostic factors in human breast carcinoma.
Wu J. | 06/12/2021 |
| The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma. | The association between the expression of PD-L1 and CMTM6 in undifferentiated pleomorphic sarcoma.
Ishihara S, Iwasaki T, Kohashi K, Yamada Y, Toda Y, Ito Y, Susuki Y, Kawaguchi K, Takamatsu D, Kawatoko S, Kiyozawa D, Mori T, Kinoshita I, Yamamoto H, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Nakashima Y, Oda Y. | 06/12/2021 |